Plus Therapeutics receives $1.9 million payment from cancer research fund

Plus Therapeutics (PSTV) received a $1.9 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT), part of a $17.6 million non-dilutive grant, to advance its targeted radiotherapeutics for leptomeningeal cancer, despite a $16.9 million negative free cash flow over the last twelve months. This funding supports clinical development of REYOBIQ and the CNSide LM diagnostic, while the company also regained Nasdaq compliance and saw D. Boral Capital upgrade its stock to a Buy rating with a $5.00 price target. Additionally, its CNSide Diagnostics subsidiary received CMS accreditation, signaling operational maturity amidst stock volatility.

Analysis

Plus Therapeutics (PSTV) has secured a $1.9 million advance payment, the second installment of a $17.6 million non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT), bolstering its development of radiotherapeutics for high-unmet-need cancers. This funding provides a degree of operational runway, with an additional $1.9 million anticipated over the next 12 months. However, this positive catalyst is set against a challenging financial backdrop, as the company is rapidly burning through cash, evidenced by a negative free cash flow of $16.9 million in the last twelve months against a modest market capitalization of approximately $41 million. The company's need for capital is further highlighted by its stated pursuit of additional grants. Operationally, PSTV has achieved positive milestones, including regaining Nasdaq compliance on stockholders' equity, receiving an extended deadline for its minimum bid price requirement, and securing a 'Buy' rating upgrade from D. Boral Capital with a $5.00 price target. This contrasts with the stock's significant volatility, which includes a 65% decline over the past six months, underscoring the high-risk, high-reward nature of this pre-commercial biotech firm.

Key Decisions for Investors

• Investors should weigh the non-dilutive CPRIT funding and positive regulatory and analyst updates against the significant financial risk posed by the company's high cash burn rate relative to its small market capitalization.
• Given the stock's extreme volatility, with a 65% decline over six months followed by a recent strong quarter, any position should be sized for a high-risk profile, with upcoming clinical trial data for REYOBIQ serving as a primary potential catalyst.
• It is critical to monitor the company's ability to secure additional non-dilutive funding and maintain Nasdaq compliance, particularly meeting the $1.00 minimum bid price rule by the November 12, 2025 deadline, as these are key de-risking events.